MX2021012960A - Composiciones y metodos de uso de cannabinoides para neuroproteccion. - Google Patents

Composiciones y metodos de uso de cannabinoides para neuroproteccion.

Info

Publication number
MX2021012960A
MX2021012960A MX2021012960A MX2021012960A MX2021012960A MX 2021012960 A MX2021012960 A MX 2021012960A MX 2021012960 A MX2021012960 A MX 2021012960A MX 2021012960 A MX2021012960 A MX 2021012960A MX 2021012960 A MX2021012960 A MX 2021012960A
Authority
MX
Mexico
Prior art keywords
neuroprotection
compositions
methods
cannabinoids
neuroprotective composition
Prior art date
Application number
MX2021012960A
Other languages
English (en)
Spanish (es)
Inventor
Eric Hsu
Ujendra Kumar
Rishi Kumar Somvanshi
Shenglong Zou
Original Assignee
Inmed Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inmed Pharmaceuticals Inc filed Critical Inmed Pharmaceuticals Inc
Publication of MX2021012960A publication Critical patent/MX2021012960A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2021012960A 2019-04-24 2020-04-24 Composiciones y metodos de uso de cannabinoides para neuroproteccion. MX2021012960A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962838216P 2019-04-24 2019-04-24
PCT/CA2020/050547 WO2020215164A1 (en) 2019-04-24 2020-04-24 Compositions and methods for use of cannabinoids for neuroprotection

Publications (1)

Publication Number Publication Date
MX2021012960A true MX2021012960A (es) 2022-01-04

Family

ID=72940570

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021012960A MX2021012960A (es) 2019-04-24 2020-04-24 Composiciones y metodos de uso de cannabinoides para neuroproteccion.

Country Status (11)

Country Link
US (1) US20230043428A1 (cg-RX-API-DMAC7.html)
EP (1) EP3958856A4 (cg-RX-API-DMAC7.html)
JP (1) JP7633179B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220080045A (cg-RX-API-DMAC7.html)
CN (1) CN114007603A (cg-RX-API-DMAC7.html)
AU (1) AU2020261515B2 (cg-RX-API-DMAC7.html)
CA (1) CA3134764A1 (cg-RX-API-DMAC7.html)
IL (1) IL287536B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021012960A (cg-RX-API-DMAC7.html)
SG (1) SG11202111809XA (cg-RX-API-DMAC7.html)
WO (1) WO2020215164A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115006404A (zh) * 2022-08-09 2022-09-06 昆药集团股份有限公司 一种具有视神经保护功效的药物组合物及其应用
US20240139272A1 (en) * 2022-10-27 2024-05-02 Kemin Industries, Inc. Use of a spearmint extract for retina neurotrophism
AU2024206205A1 (en) * 2023-01-04 2025-07-17 Florascience Inc. Cannabinoids for use in the treatment of a neurodegenerative disease or condition
IL327899A (en) * 2023-10-23 2026-06-01 Inmed Pharmaceuticals Inc Compositions and methods for use of cannabinol compounds in neuroprotection

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2471987B (en) * 2008-06-04 2012-02-22 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
BR112013012468A2 (pt) * 2010-11-18 2016-09-06 Pier Pharmaceuticals método de tratar um indivíduo com um distúrbio sensível a canabinóide, de estabelecer uma dose ideal, de tratar um indivíduo com um distúrbio de apneia do sono, e, kit
MX2017005277A (es) * 2014-10-21 2018-01-11 United Cannabis Corp Extractos de cannabis y métodos de preparación y uso de la misma.
MA41299A (fr) * 2014-12-30 2017-11-07 Axim Biotechnologies Inc Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite
US20170266153A1 (en) * 2015-02-27 2017-09-21 Ebbu, LLC Compositions purposefully selected comprising purified cannabinoids and/or purified terpenes
AU2016225026A1 (en) * 2015-02-27 2017-09-07 Canopy Growth Corporation Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral
EP3261629A4 (en) * 2015-02-27 2018-12-05 Ebbu, LLC Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral
US20160282371A1 (en) * 2015-03-28 2016-09-29 Quantalytical Labs Inc. Solid Phase Extraction, Derivatization with Crown Ethers, and Mass Spectrometry, Methods, Reagents and Kits
IL248149B (en) * 2016-09-29 2020-03-31 Garti Nissim Dilutable formulations of cannbinoids and processes for their preparation
JP7225103B2 (ja) * 2016-10-11 2023-02-20 ジービーエス グローバル バイオファーマ,インコーポレイテッド 神経変性疾患を処置するためのカンナビノイド含有複合混合物
WO2018118197A1 (en) * 2016-12-21 2018-06-28 Richard Postrel Healthier aging in domesticated animals
CN110997006A (zh) * 2017-05-08 2020-04-10 因美制药公司 眼部药物递送制剂
WO2018205038A1 (en) * 2017-05-12 2018-11-15 Tetra Bio-Pharma Inc. Compositions comprising cannabinoids and terpenes useful in the treatment of cancer and vascular ocular disorders via inhibition of hedgehog signalling
US20170348277A1 (en) * 2017-08-02 2017-12-07 Bryan Ray Ruiz Cannabinoid formulation including a vasodilator and ocular delivery of the same

Also Published As

Publication number Publication date
JP7633179B2 (ja) 2025-02-19
AU2020261515B2 (en) 2025-10-23
EP3958856A1 (en) 2022-03-02
SG11202111809XA (en) 2021-11-29
CA3134764A1 (en) 2020-10-29
US20230043428A1 (en) 2023-02-09
KR20220080045A (ko) 2022-06-14
IL287536A (en) 2021-12-01
EP3958856A4 (en) 2023-01-25
IL287536B2 (en) 2026-03-01
WO2020215164A1 (en) 2020-10-29
AU2020261515A1 (en) 2021-11-18
CN114007603A (zh) 2022-02-01
IL287536B1 (en) 2025-11-01
JP2022530471A (ja) 2022-06-29

Similar Documents

Publication Publication Date Title
CO2019007810A2 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
CO2020015758A2 (es) Compuestos de purinona y su uso en el tratamiento del cáncer
ECSP18073293A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
ECSP18073264A (es) Derivados de compuestos de indol sustituidos como inhibidores de la replicación vírica del dengue
ECSP20046463A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
NI201900099A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CR20190063A (es) 3-metil pirazinas 2,5-disustituídas y 3-metil pirazinas 2,5,6-trisustituídas como inhibidores alostéricos de shp2
MX2019002564A (es) Composiciones de agente de unión de albúmina-paclitaxel y métodos de uso y elaboración de las mismas.
UY37435A (es) Pirrolidinas sustituidas y métodos para usarlas
UY37741A (es) Derivados de indolina sustituidos como inhibidores de la replicación del virus del dengue
UY30058A1 (es) (indazol-5-il)-piracinas y (1,3-dihidro-indol-2-on)-piracinas para el tratamiento de enfermedades y afecciones mediadas por la rho quinasa
NI201900098A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP19083640A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP18073245A (es) Derivados de indol sustituidos como inhibidores de la replicación vírica del dengue
ECSP18073366A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
UY36465A (es) Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico
PE20181165A1 (es) Derivados de indol mono-o disustituidos como inhibidores de la replicacion viral del dengue
CO2018005971A2 (es) Composición de regulador de crecimiento vegetal que tiene efecto sinérgico
MX2017003788A (es) Derivados de nucleósidos sustituidos con 4´-vinilo como inhibidores de la replicación del arn del virus respiratorio sincitial.
MX2020012014A (es) Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.
DOP2019000221A (es) Derivados de pirazol como inhibidores de bromodominio
UY37555A (es) Derivados de ácido piridin-3-il-acético como inhibidores de la replicación del virus de la inmunodeficiencia humana
CO2021004612A2 (es) Derivados de 4 pirazin 2 ilmetil-morfolina y su uso como medicamento
CO2017003848A1 (es) Composición que comprende extractos de guadua angustifolia para la prevención o el tratamiento de enfermedades de la retina
MX2020009396A (es) Metodos de uso y composiciones farmaceuticas de un inhibidor selectivo de syk.